AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01725529
Drug: Ribavirin (RBV)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin 1000 or 1200 mg/day (taken as 100 mg or 200 mg tablets) depending on body weight (If body weight is \< 75 kg the total daily dose of RBV will be 1000 mg, administered as 400 mg intake with food in the morning and 600 mg intake with food in the evening. If body weight is \> or = 75 kg the total daily dose will be 1200 mg, administered as 2 x 600 mg per intake with food, morning and evening) for 24 or 48 weeks.
Trial: NCT02371447
Drug: VPM1002BC
DrugBank: VPM1002 (DB15801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1:~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)~Phase 2:~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)
Trial: NCT00133991
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.
Trial: NCT01442688
Drug: Amoxicillin + MMX placebo
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMX placebo administered once a day (QD) orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX placebo on Day 4.
Trial: NCT01503424
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine Tablets, 5 mg
Trial: NCT02997202
Drug: gilteritinib
RxNorm normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral
Trial: NCT01199133
Drug: 300 IR house dust mites allergen extract tablet
RxNorm normalized name: European house dust mite allergenic extract
DrugBank: House dust (DB10345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One sublingual tablet daily for one year.
Trial: NCT00133991
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg on Days 1-5 of each cycle of R-CVP.
Trial: NCT00133991
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m\^2 on Day 1 of each cycle of R-CVP.
Trial: NCT00634309
Drug: Candesartan
RxNorm normalized name: Candesartan
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01442688
Drug: Amoxicillin + MMX mesalazine/mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMX mesalazine/mesalamine (4.8 g) administered QD orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX mesalazine/mesalamine (4.8 g) on Day 4.
Trial: NCT02244567
Drug: Metformin 850 mg twice daily for 3 months
RxNorm normalized name: metformin hydrochloride 850 MG
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This drug is insulin sensitizing agent which will be given twice daily orally for 3 months for PCOS patients.
Trial: NCT01931657
Drug: Mifepristone prior to Mirena
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00906087
Drug: Cosopt (combination eyedrop of dorzolamide and timolol)
RxNorm normalized name: dorzolamide / timolol Ophthalmic Solution [Cosopt]
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One drop in each eye every twelve hours for six weeks
Trial: NCT02103998
Drug: thryoid hormone T4 + oral potassium iodide (KI) for 42 days
RxNorm normalized name: Potassium Iodide
DrugBank: Potassium Iodide (DB06715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
Trial: NCT02103998
Drug: D5W - 5% dextrose water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equivalent volume of infusion as study drug
Trial: NCT02662036
Drug: Bupivicaine HCL
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02662036
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03029143
Drug: Vedolizumab IV
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab intravenous infusion.
Trial: NCT01384227
Drug: Proflavine Hemisulfate
RxNorm normalized name: Proflavine hemisulfate
DrugBank: Proflavine (DB01123)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proflavine hemisulfate 0.01% (derived from dissolving 10 mg Proflavine Hemisulfate USP in 100 ml of sterile water)
Trial: NCT01662674
Drug: gemigliptin and metformin HCl extended release
RxNorm normalized name: metformin hydrochloride Extended Release Suspension
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
Trial: NCT01662674
Drug: gemigliptin/metformin HCl extended release
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
Trial: NCT00440947
Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV)+ ritoanvir (/r) for 36weeks followed by ABC/3TC + ATV + /r for 48wks followed by optional treatment extension for 60 weeks on the same regimen
Trial: NCT00440947
Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV) + ritonavir (/r) for 36 weeks followed by ABC/3TC + ATV for 48wks followed by optional treatment extension for 60 weeks on the same regimen
Trial: NCT00942968
Drug: dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous injection 200IU/kg dalteparin
Trial: NCT01978743
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks
Trial: NCT01472848
Drug: PF 05212389 or placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
Trial: NCT01472848
Drug: PF 05212389 or placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
Trial: NCT00120198
Drug: CDOP plus rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01452815
Drug: 10mg TZP-102
RxNorm normalized name: TZP-102
DrugBank: TZP-102 (DB16129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 10mg #2 oval shaped, opaque-white, hard gelatin shell capsule containing active ingredients and one placebo capsule each taken orally once daily for 12 Weeks
Trial: NCT01452815
Drug: 20mg TZP-102
RxNorm normalized name: TZP-102
DrugBank: TZP-102 (DB16129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 10mg #2 oval shaped, opaque-white, hard gelatin shell capsules containing active ingredients
Trial: NCT02992340
Drug: Varlitinib
RxNorm normalized name: Varlitinib
DrugBank: Varlitinib (DB05944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per oral (PO) Varlitinib BID (starting dose at 200 mg BID)
Trial: NCT02992340
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On D1 and D8, every 3 weeks. Cisplatin (25 mg per square meter of body surface area) in 1 litre of 0.9% saline with 20 mmol of potassium chloride and 8 mmol of magnesium sulfate intravenous (IV) infusion for 2 hours, followed by 500 mL of 0.9% saline over 30 minutes before the administration of Gemcitabine
Trial: NCT02992340
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On D1 and D8, every 3 weeks. Gemcitabine (1000 mg per square meter of body surface area) as a 30-minute infusion.
Trial: NCT03473197
Drug: Diacerein 1% ointment
DrugBank: Diacerein (DB11994)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the 3-week Induction Phase, diacerein 1% ointment and vehicle ointment were applied under fully occlusive patch conditions to two randomly assigned skin sites on the infrascapular region of the back twice each week for approximately 24 hours (±4 hours). After patch removal, one application site and an untreated control site was irradiated, and all sites were evaluated 24 hours, 48 hours, and 72 hours later. Following a rest period, during the Challenge Phase, the study products were applied to two naive sites once for approximately 24 hours (±4 hours). After patch removal, one application site and an untreated control site was irradiated, and all sites were evaluated 24 hours, 48 hours, and 72 hours later. A Re-Challenge was to be performed if a response observed during the Challenge Phase indicated photosensitization.
Trial: NCT00781911
Drug: depot octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
Trial: NCT00267670
Drug: Pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg PO TID
Trial: NCT00785629
Drug: Lanthanum Carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03317795
Drug: Levonorgestrel IUS
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LNG-IUS was FDA-approved for the treatment of heavy menstrual bleeding in 2009 and previously for contraception in 2000. The LNG-IUS is a T-shaped device with a polyethylene body containing a hormone reservoir, holding a total of 52 mg of levonorgestrel. LNG-IUS initially releases 20 micrograms of the progestin per day, which decreases to less than half that amount after 5 years of use. The levonorgestrel causes stromal pseudodecidualization, decreases endometrial thickness, and lowers uterine vascular density.
Trial: NCT03317795
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic Acid was FDA-approved for the treatment of heavy menstrual bleeding in 2009. Tranexamic Acid is a plasminogen-activator inhibitor that blocks fibrinolysis and reduces plasmin activity. A special formulation was designed for the treatment of heavy menstrual bleeding that reduces gastrointestinal side effects, brand name Lysteda which will be prescribed as 1300 mg to be taken three times per day for up to 5 days of the menstrual period.
Trial: NCT01202422
Drug: Pregabalin controlled release, 165 mg
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Two tablets of 165 mg controlled release (administered concurrently) once daily for four days.
Trial: NCT01202422
Drug: Pregabalin controlled release, 330 mg
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 330 mg controlled release tablet administered once daily for four days.
Trial: NCT02718755
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction Phase:~30 mg/m2 by vein over 15-30 minutes on Days 1 - 5 of a 28 day cycle.~Consolidation Phase:~30 mg/m2 by vein over 15-30 minutes on Days 1 - 4 of a 28 day cycle.
Trial: NCT02718755
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction Phase:~2 grams/m2 by vein over approximately 2 hours on Days 1 - 5 of a 28 day cycle.~Consolidation Phase:~2 grams/m2 by vein over approximately 2 hours on Days 1 - 4 of a 28 day cycle.
Trial: NCT02718755
Drug: Erwinase
RxNorm normalized name: Erwinase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction Phase:~25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes on Days 1 - 7 of a 28 day cycle.~Consolidation Phase:~25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes every other day on Days 1, 3, 5, 7, 9, 11, 13, 15 of a 28 day cycle.
Trial: NCT01202422
Drug: Pregabalin immediate release, 150 mg
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 150 mg immediate release capsules administered every 12 hours for four days
Trial: NCT02642367
Drug: rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tracehal intubation was performed 2 min after rocuronium injection with McGrath videolaryngoscope
Trial: NCT00785629
Drug: Sevelamer Carbonate
RxNorm normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02339207
Drug: AL-335
RxNorm normalized name: Al
DrugBank: Aluminium (DB01370)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00771602
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m\^2 by standard IV (intravenous) infusion on days 1, 8, 15, and 22 of weeks 1-4.
Trial: NCT01530984
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 3 mg/kg on day 1 of a 28 day cycle for 6 cycles.
Trial: NCT01530984
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF 250 mcg/m2 SQ on days 1-14 for 6 cycles.
Trial: NCT02477059
Drug: tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Le tocilizumab is administered by intravenous infusion at a dose of 8 mg / kg.
Trial: NCT02477059
Drug: saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: La saline solution is administered by intravenous infusion.
Trial: NCT02567149
Drug: Cidofovir
RxNorm normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cidofovir
Trial: NCT00771602
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose escalation of 3, 10 and 30 mg subcutaneously (SQ) during week 1, followed by dose of 30 mg subcutaneously three times weekly (e.g. Monday-Wednesday - Friday) starting on week 2 for a total of 12 weeks (2-13).
Trial: NCT02517684
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02648906
Drug: Choline alfoscerate
RxNorm normalized name: Choline Alfoscerate
DrugBank: Choline alfoscerate (DB04660)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01069536
Drug: metoclopramide 10 mg
RxNorm normalized name: metoclopramide 10 MG
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02290873
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For induction and maintenance of sedation
Trial: NCT02290873
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For induction of maintenance and sedation
Trial: NCT01108029
Drug: memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 tablets of 10 mg of memantine 1 time a day in the morning
Trial: NCT00885274
Drug: Pico-Salax
RxNorm normalized name: SALIX
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both doses of Pico-Salax taken the evening prior to colonoscopy
Trial: NCT00885274
Drug: Split Dose Pico-Salax
RxNorm normalized name: SALIX
DrugBank: Willow bark (DB14691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of Pico-Salax taken the evening prior to colonoscopy and the other the morning of the procedure.
Trial: NCT00259883
Drug: paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 or 2 tablets once a day
Trial: NCT03154814
Drug: ulinastatin
RxNorm normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ulinastatin (10000 U/kg and 5000 U/kg/h) was administered during CPB
Trial: NCT03154814
Drug: control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: conventional CPB was applied without ulinastatin treatment
Trial: NCT01230541
Drug: Udenafil
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily tablet
Trial: NCT01755078
Drug: Sevelamer HCl
RxNorm normalized name: SEVELAMER HCL
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-metal phosphate binder
Trial: NCT02595476
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04247633
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib at a dose of 125 mg will be administered orally once a day for 21 days, followed by 7 days off treatment of every 28 day cycle. Investigational medicinal product (IMP) will be administered with standard adjuvant endocrine therapy (Non-investigational treatment).
Trial: NCT00692341
Drug: AG-013736
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
Trial: NCT00561834
Drug: ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients (n=15) will be treated with open label 0.5mg ranibizumab given intravitreally monthly as needed for 6 months.
Trial: NCT00139711
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00139711
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00747097
Drug: gemcitabine + cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: gemcitabine 1g/m² 3weeks/4 cetuximab 400 mg/m² the first week, then 250 mg/m², every week Every cycle is 8 weeks treatment
Trial: NCT01969747
Drug: Empagliflozin medium placebo
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin medium placebo
Trial: NCT01930123
Drug: intravenous fructose challenge
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be admitted to our Duke Clinical Research Unit (DCRU) at least 12 hours prior to morning intravenous fructose challenge. All patients will have a standard meal in order to control for dietary composition and calorie intake prior to intravenous fructose challenge. Patients will be NPO (nothing by mouth) after midnight for morning IV fructose MR biomarker measures. Patients with suspected NAFLD will have had an historical standard of care liver biopsy in the past and will have IV fructose Magnetic Resonance biomarker measures in the morning.
Trial: NCT01969747
Drug: Empagliflozin low placebo
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin low placebo
Trial: NCT01969747
Drug: Empagliflozin high placebo
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin high placebo
Trial: NCT01969747
Drug: Empagliflozin medium
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin medium
Trial: NCT01969747
Drug: Empagliflozin low
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin low
Trial: NCT01969747
Drug: Empagliflozin high
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin high
Trial: NCT01900340
Drug: Exendin 9-39
RxNorm normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV exendin(9-39) infusion and intraduodenal administration of saline via feeding tube
Trial: NCT01900340
Drug: Exendin(9-39) plus ID nutrient
RxNorm normalized name: EXENDIN (9-39)
DrugBank: Avexitide (DB14806)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration
Trial: NCT00316186
Drug: topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
Trial: NCT00316186
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.